Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Josh Paterson
The BCL-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect With Dexamethasone and Melphalan
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Synergistic BCL-2 Inhibition by ABT-737 and Cyclosporine A
Apoptosis : an international journal on programmed cell death
Cell Biology
Pharmacology
Biochemistry
Clinical Biochemistry
Cancer Research
Pharmaceutical Science
Crystal Structure of ABT-737 Complexed With BCL-xL: Implications for Selectivity of Antagonists of the BCL-2 Family
Cell Death and Differentiation
Cell Biology
Molecular Biology
Combined Inhibition of Notch Signaling and BCL-2/BCL-xL Results in Synergistic Antimyeloma Effect
Molecular Cancer Therapeutics
Cancer Research
Oncology
BCL-xL-Inhibitory BH3 Mimetics (ABT-737 or ABT-263) and the Modulation of Cytosolic Calcium Flux and Platelet Function
Blood
Biochemistry
Immunology
Cell Biology
Hematology
ABT-737, a Small Molecule BCL-2/BCL-xL Antagonist, Increases Antimitotic-Mediated Apoptosis in Human Prostate Cancer Cells
PeerJ
Genetics
Molecular Biology
Biochemistry
Biological Sciences
Medicine
Agricultural
Neuroscience
Adenovirus E4orf6 Suppresses the Apoptotic Activity by BCL-2 Family Protein, BNIP3.
Japanese Journal of Oral Biology
The BCL-2 Protein Family, BH3-mimetics and Cancer Therapy
Cell Death and Differentiation
Cell Biology
Molecular Biology
Metabolic Changes Associated With Metformin Potentiates Anti-BCL-2 Inhibitor, Abt-199, and Cdk9 Inhibitor, Bay-1143572 and Reduces Viability of Lymphoma Cells
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells With a BCL-2high/McL-1low Profile and Synergizes With Other Antineoplastic Agents
Clinical Cancer Research
Cancer Research
Oncology
